{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:13:41Z","timestamp":1774084421321,"version":"3.50.1"},"reference-count":39,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2017.00652","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T04:22:36Z","timestamp":1506313356000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Molecular Guided Therapy Provides Sustained Clinical Response in Refractory Choroid Plexus Carcinoma"],"prefix":"10.3389","volume":"8","author":[{"given":"Albert","family":"Cornelius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Foley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Bond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinav B.","family":"Nagulapally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Steinbrecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William P. D.","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Rich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangeeta","family":"Yendrembam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve","family":"Bergendahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Trent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giselle S.","family":"Sholler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1038\/cddis.2017.80","article-title":"p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo","volume":"8","author":"Alexandrova","year":"2017","journal-title":"Cell Death Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11060-010-0372-9","article-title":"Which therapy works better in choroid plexus carcinomas?","volume":"103","author":"Berrak","year":"2011","journal-title":"J. Neurooncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3171\/2012.8.PEDS12132","article-title":"Treatment of choroid plexus tumors: a 20-year single institutional experience","volume":"10","author":"Bettegowda","year":"2012","journal-title":"J. Neurosurg. Pediatr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s12032-014-0985-5","article-title":"Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience","volume":"31","author":"Bezecny","year":"2014","journal-title":"Med. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/0092-8674(84)90367-2","article-title":"Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors","volume":"37","author":"Brinster","year":"1984","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1158\/0008-5472.CAN-09-3028","article-title":"Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage","volume":"70","author":"Conti","year":"2010","journal-title":"Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e18015","DOI":"10.1371\/journal.pone.0018015","article-title":"Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil","volume":"6","author":"Custodio","year":"2011","journal-title":"PLoS ONE"},{"key":"B9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molmed.2010.07.002","article-title":"IDH mutations in glioma and acute myeloid leukemia","volume":"16","author":"Dang","year":"2010","journal-title":"Trends Mol. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.bbapap.2009.12.001","article-title":"Dissecting the role of mTOR: lessons from mTOR inhibitors","volume":"1804","author":"Dowling","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"B11","doi-asserted-by":"publisher","first-page":"8204","DOI":"10.1073\/pnas.0502857102","article-title":"The coordinate regulation of the p53 and mTOR pathways in cells","volume":"102","author":"Feng","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B12","first-page":"1043","article-title":"Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck","volume":"1","author":"Gonzalez","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"6976","DOI":"10.1038\/sj.onc.1208839","article-title":"The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library","volume":"24","author":"Kawaguchi","year":"2005","journal-title":"Oncogene"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2353\/ajpath.2009.081022","article-title":"Platelet-derived growth factor receptor expression and activation in choroid plexus tumors","volume":"175","author":"Koos","year":"2009","journal-title":"Am. J. Pathol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/cdd.2011.71","article-title":"SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis","volume":"18","author":"Li","year":"2011","journal-title":"Cell Death Differ."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/onc.2013.193","article-title":"Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene","volume":"33","author":"Martin","year":"2014","journal-title":"Oncogene"},{"key":"B19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/1078-0432.CCR-14-1324","article-title":"Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups","volume":"21","author":"Merino","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3109\/02688697.2011.601820","article-title":"Choroid plexus tumors in pediatric patients","volume":"26","author":"Ogiwara","year":"2012","journal-title":"Br. J. Neurosurg."},{"key":"B21","first-page":"6643","article-title":"Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype","volume":"63","author":"Olivier","year":"2003","journal-title":"Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fonc.2015.00288","article-title":"Targeting oncogenic mutant p53 for cancer therapy","volume":"5","author":"Parrales","year":"2015","journal-title":"Front. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/pbc.24006","article-title":"Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors","volume":"59","author":"Peyrl","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","article-title":"Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway","volume":"142","author":"Polivka","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/pbc.25045","article-title":"Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma","volume":"61","author":"Porkholm","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern cooperative oncology group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0002-9440(10)64931-0","article-title":"Chromosomal imbalances in choroid plexus tumors","volume":"160","author":"Rickert","year":"2002","journal-title":"Am. J. Pathol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/gcc.22148","article-title":"Choroid plexus carcinomas are characterized by complex chromosomal alterations related to patient age and prognosis","volume":"53","author":"Ruland","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1128\/MCB.14.4.2686","article-title":"Induction versus progression of brain tumor development: differential functions for the pRB- and p53-targeting domains of simian virus 40 T antigen","volume":"14","author":"Saenz Robles","year":"1994","journal-title":"Mol. Cell. Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/cam4.436","article-title":"Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma","volume":"4","author":"Saulnier Sholler","year":"2015","journal-title":"Cancer Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1086\/302639","article-title":"Constitutional mutations of the hSNF5\/INI1 gene predispose to a variety of cancers","volume":"65","author":"Sevenet","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10143-013-0499-1","article-title":"Current management of choroid plexus carcinomas","volume":"37","author":"Sun","year":"2014","journal-title":"Neurosurg. Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.2009.26.8169","article-title":"TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors","volume":"28","author":"Tabori","year":"2010","journal-title":"J. Clin. Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1200\/JCO.2009.22.7967","article-title":"2009 version of the Chompret criteria for Li Fraumeni syndrome","volume":"27","author":"Tinat","year":"2009","journal-title":"J. Clin. Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.ccell.2015.04.005","article-title":"Cross-Species genomics identifies TAF12, NFYC, and RAD54L as choroid plexus Carcinoma oncogenes","volume":"27","author":"Tong","year":"2015","journal-title":"Cancer Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.cell.2014.01.066","article-title":"Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling","volume":"157","author":"Weissmueller","year":"2014","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11060-007-9428-x","article-title":"Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors","volume":"85","author":"Wrede","year":"2007","journal-title":"J. Neurooncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-12-1773","article-title":"IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives","volume":"18","author":"Yang","year":"2012","journal-title":"Clin. Cancer Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00652\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T04:22:39Z","timestamp":1506313359000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00652\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,25]]},"references-count":39,"alternative-id":["10.3389\/fphar.2017.00652"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2017.00652","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,25]]},"article-number":"652"}}